000118218 001__ 118218 000118218 005__ 20240319081021.0 000118218 0247_ $$2doi$$a10.1186/s12931-022-02092-9 000118218 0248_ $$2sideral$$a129616 000118218 037__ $$aART-2022-129616 000118218 041__ $$aeng 000118218 100__ $$aMarín-Oto, M. 000118218 245__ $$aSoluble RAGE in COPD, with or without coexisting obstructive sleep apnoea 000118218 260__ $$c2022 000118218 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118218 5203_ $$aBackground: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-inflammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers HNS], 84 healthy smokers HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap). Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (- 12.5%, p = 0.005), COPD (- 14.8%, p < 0.001) and OSA-COPD overlap (- 12.3%, p = 0.02) compared with HNS. There were no differences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change significantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased significantly. Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD. 000118218 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FIS/PI18-01524$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02175$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01940 000118218 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000118218 590__ $$a5.8$$b2022 000118218 592__ $$a1.753$$b2022 000118218 591__ $$aRESPIRATORY SYSTEM$$b15 / 66 = 0.227$$c2022$$dQ1$$eT1 000118218 593__ $$aPulmonary and Respiratory Medicine$$c2022$$dQ1 000118218 594__ $$a9.5$$b2022 000118218 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118218 700__ $$0(orcid)0000-0002-5228-248X$$aSanz-Rubio, D. 000118218 700__ $$aSantamaría-Martos, F. 000118218 700__ $$aBenitez, I. 000118218 700__ $$aSimon, A. L. 000118218 700__ $$aForner, M. 000118218 700__ $$aCubero, P. 000118218 700__ $$aGil, A. 000118218 700__ $$aSánchez de la Torre, M. 000118218 700__ $$aBarbe, F. 000118218 700__ $$0(orcid)0000-0001-9096-2294$$aMarín, J. M.$$uUniversidad de Zaragoza 000118218 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000118218 773__ $$g23 (2022), 163 [9 pp.]$$pRespir. res.$$tRespiratory Research$$x1465-9921 000118218 8564_ $$s1114956$$uhttps://zaguan.unizar.es/record/118218/files/texto_completo.pdf$$yVersión publicada 000118218 8564_ $$s2473907$$uhttps://zaguan.unizar.es/record/118218/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118218 909CO $$ooai:zaguan.unizar.es:118218$$particulos$$pdriver 000118218 951__ $$a2024-03-18-16:14:29 000118218 980__ $$aARTICLE